New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum-and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an anti-body-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV. (C) 2021 Published by Elsevier Inc.

Automated summary

Enfortumab vedotin (EV) is a newly approved drug for platinum-and checkpoint-refractory urothelial cancer, with a high response rate. However, not all patients benefit from this treatment, and the mechanisms of treatment resistance remain unclear. Additional research is needed to further understand the response to EV therapy.